X4 Pharmaceuticals Inc Stock Price, News & Analysis

X4 Pharmaceuticals (Nasdaq: XFOR) announced it will report its financial results for the fourth quarter and full year ending December 31, 2022, on March 21, 2023. A conference call will follow at 9:00 a.m. ET to discuss these results and recent business highlights. X4 is focused on developing mavorixafor, a novel therapy for chronic neutropenic disorders, including WHIM syndrome. The company is preparing for a U.S. regulatory submission after positive Phase 3 trial results. The investor webcast will be available on X4's website post-call.

X4 Pharmaceuticals (Nasdaq: XFOR) announced the issuance of inducement awards for new employees, totaling 54,900 options to purchase common stock at an exercise price of $0.94 per share. These awards, granted under the 2019 Inducement Equity Incentive Plan, were approved by the board's compensation committee and are part of Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with 25% vesting after one year. X4 focuses on developing therapies for immune system diseases, with its lead candidate mavorixafor showing promise in treating WHIM syndrome, currently preparing for a U.S. regulatory submission after positive Phase 3 trial results.

X4 Pharmaceuticals has announced positive developments regarding its clinical candidate mavorixafor for treating chronic neutropenic disorders. Highlights from the Phase 1b clinical trial presented at the American Society of Hematology meeting indicate that a single oral dose significantly increased absolute neutrophil count (ANC) across all participants, with overall good tolerance. The company also revealed that between 37,000–48,000 people in the U.S. have chronic neutropenia, emphasizing the substantial unmet medical needs in this patient population.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced a public offering of 52.3 million shares, including pre-funded warrants for 6.8 million shares, alongside Class C warrants for 29.55 million shares, priced at $1.10 each. The offering aims to raise approximately $65 million, or up to $74.8 million if the underwriters' option is exercised. The offering is expected to close on December 9, 2022. Piper Sandler, Stifel, and Cantor are the joint book-running managers. The offering is filed under a shelf registration statement with the SEC.

X4 Pharmaceuticals (Nasdaq: XFOR) has announced an underwritten public offering of its common stock and accompanying warrants. The offering, conducted by Piper Sandler, Stifel, and Cantor, includes a 30-day option for underwriters to purchase additional shares. The offering's completion is subject to market conditions, and no assurance is provided regarding the final terms. X4 is focused on developing mavorixafor, a treatment for immune system diseases, particularly chronic neutropenic disorders.

X4 Pharmaceuticals announced positive top-line results from its Phase 3 clinical trial (4WHIM) of mavorixafor for WHIM syndrome. The trial met its primary endpoint, demonstrating clinical superiority over placebo in increasing absolute neutrophil counts (P < 0.0001) and absolute lymphocyte counts (P < 0.0001). Mavorixafor was well tolerated, with no serious adverse events reported. Following the trial, over 90% of participants chose to continue treatment, highlighting its potential. The company aims to meet U.S. regulatory authorities in early 2023 for further steps towards regulatory approval.

X4 Pharmaceuticals (Nasdaq: XFOR) announced management's participation in a fireside chat at the Stifel Healthcare Conference on November 15, 2022, at 3:00 PM ET. The event will be streamed live on their website, with an archive available for 90 days post-event. X4 Pharmaceuticals focuses on novel therapies for immune system diseases, including their leading candidate, mavorixafor, a small-molecule therapy targeting CXCR4, currently in global Phase 3 trials for WHIM syndrome.

Scorpion Therapeutics has announced the formation of a Clinical Scientific Advisory Board (Clinical SAB) to enhance its Precision Oncology 2.0 strategy. This board comprises esteemed physician-scientists specialized in cancer treatment and development. The Clinical SAB will provide insights to expedite the company's lead programs, including STX-478 and STX-721, aimed at advancing toward investigational new drug applications in 2023. CEO Axel Hoos expressed optimism about the expertise of the members and their potential impact on improving cancer therapies.

X4 Pharmaceuticals (Nasdaq: XFOR) announced the issuance of inducement awards for new employees under the 2019 Inducement Equity Incentive Plan. On November 3, 2022, the company granted options to purchase 410,000 shares of its common stock, with 341,000 shares awarded to the new Chief Commercial Officer, Mark Baldry. The options have a ten-year term and an exercise price of $1.89 per share, matching the closing price on the grant date. Vesting occurs over four years, contingent on continued employment. X4 focuses on developing therapies for immune system diseases, including its lead candidate mavorixafor.